Table 1 Baseline characteristics of included studies. Included studies classifications of First Author, Year, Country, Study Type, Type of JAK-inhibitor/Type I interferon Used, Total Number of Participants, Number of Participants Receiving JAK-inhibitor/Type I interferon Used. Studies presented in alphabetical order by treatment group
First Author, Year | Country | Study Type | JAK-inhibitor/Interferon Used | Total # of Participants | N Participants Receiving JAK-inhibitor/Interferona |
|---|---|---|---|---|---|
Bronte 2020 [25] | Italy | Observational | Baricitinib | 76 | 20 |
Cantini 2020a [26] | Italy | Retrospective Cohort | Baricitinib | 191 | 113 |
Cantini 2020b [27] | Italy | Prospective Cohort, open-label | Baricitinib | 24 | 12 |
Cao 2020 [28] | China | RCT | Ruxolitinib | 41 | 20 |
Giudice 2020 [29] | Italy | RCT | Ruxolitinib | 17 | 7 |
Chen 2020 [30] | China | Observational | IFN-alpha-2b | 291 | 132 |
Davoudi-Monfared 2020 [31] | Iran | RCT | IFN-beta-1a | 81 | 42 |
Du 2020 [32] | China | Retrospective Cohort | IFN-alpha | 182 | 178 |
Estébanez 2020 [33] | Spain | Retrospective Cohort | IFN-beta-1b | 256 | 106 |
Fan 2020 [34] | China | Retrospective Observational | IFN-alpha-1b | 53 | 19 |
Hung 2020 [35] | China | RCT | IFN-beta-1b | 127 | 86 |
Liu 2020 [36] | China | Retrospective Observational | IFN-alpha-2b | 10 | 9 |
Pereda 2020 [37] | Cuba | Retrospective Cohort | IFN-alpha-2b | 814 | 761 |
Wang 2020 [38] | China | Retrospective Cohort | IFN-alpha-2b | 446 | 242 |
Zhou 2020 [39] | China | Retrospective Cohort | IFNb | 221 | 139 |